Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHair loss affects a meaningful minority of people taking Wegovy (semaglutide), and the NHS medicines page for semaglutide lists it as a known side effect. It tends to appear in the first few months of treatment, is usually temporary, and is more closely tied to rapid weight loss than to the medicine itself. A prescriber can help you weigh this up before you start. These are prescription-only medicines; suitability is decided by a clinician after a full assessment, not by an online form alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
In the STEP 1 trial (68 weeks, semaglutide 2.4 mg versus placebo, published in the New England Journal of Medicine) average body weight fell by roughly 15% in the treatment group. That scale of weight loss, achieved relatively quickly, creates a physiological stress signal that can push hair follicles from their active growth phase (anagen) into a resting and shedding phase (telogen). The result is diffuse thinning, typically noticed two to four months after the stress event rather than immediately. Participants in the semaglutide arm did report alopecia at higher rates than placebo, which is consistent with this mechanism rather than a direct follicle-toxic effect of the drug.
The MHRA's prescribing information and the SmPC for Wegovy both list hair loss among the known side effects. It is classified as common (affecting up to 1 in 10 people) in post-marketing data. For context on what post-marketing surveillance captures, the MHRA Yellow Card scheme is where patients and clinicians report suspected side effects, real-world reporting that supplements trial data.
Telogen effluvium is self-limiting in most cases. The follicle does not die; it restarts its growth cycle once the physiological disruption settles. Shedding typically peaks around month three and slows through months four to six. That does not make it trivial (noticing clumps in the shower is distressing) but it is biologically different from the permanent hair loss seen in conditions such as alopecia areata.
The link between fast weight loss and temporary hair shedding is well established, predating GLP-1 medicines entirely. It is documented after bariatric surgery, strict very-low-calorie diets and illness-related weight loss. The common thread is caloric restriction significant enough to redirect the body's resources away from hair growth, which is metabolically expensive and non-essential in the short term.
On Wegovy, appetite falls substantially. Without conscious attention to nutrition, protein intake often drops alongside total calories. Protein provides the amino acids (particularly cysteine and methionine) that keratin production depends on. An adequate protein target (often cited at around 1.2–1.6 g per kilogram of body weight daily on a weight-loss programme, though your prescriber or a dietitian will set a personal figure) helps preserve lean mass and may reduce the degree of shedding. Iron and ferritin levels are also worth checking if hair loss is noticeable; iron deficiency is common in the general population and can independently accelerate telogen effluvium.
If you are curious about whether semaglutide specifically is implicated in hair changes beyond this mechanism, our page on whether semaglutide can cause hair loss works through the pharmacology in more detail. The short answer: the medicine appears to play a secondary role to the weight-loss process itself.
First, time matters. If the shedding started two to three months after you began Wegovy or after a significant dose increase, that timeline fits telogen effluvium almost exactly. Note when it began, how much is coming out (a handful versus visible thinning at the crown are different signals), and whether it is improving. Most people find it slows and then reverses without stopping treatment.
A few things worth doing: review your daily protein and check you are eating enough across the day, not just small amounts; ask your GP to run a blood panel including ferritin, thyroid function (TSH) and full blood count if the shedding is significant, thyroid changes can also occur during weight-loss treatment and compound hair loss; and speak to your prescriber rather than stopping Wegovy abruptly, because the clinical picture matters to any decision about continuing or pausing.
Some people find that losing hair on Wegovy coincides with the adjustment period in the first few months, then improves even as treatment continues. Others notice it correlates with a particular dose step. Keeping a simple log is more useful than trying to count hairs.
If you are comparing how this plays out against other GLP-1 medicines, our semaglutide overview covers the broader side-effect profile in context, and the Wegovy treatment page explains how the dose schedule works in practice.
On the question of cost (because this comes up, particularly for people considering whether starting treatment is worth the disruption) our Wegovy cost guide covers what UK private pricing typically includes and why the prescription and clinical oversight are part of what you are paying for, not extras.
Telogen effluvium is usually a diagnosis of exclusion and timing. That means a clinician rules out other causes rather than simply assuming weight loss is the driver. Get a GP review sooner rather than later if: the shedding is patchy rather than diffuse (patchy loss is more consistent with alopecia areata or another condition); it has continued for more than six months without any sign of slowing; you also have fatigue, cold sensitivity or unexplained weight plateau (thyroid symptoms); or you are losing eyebrows or eyelashes alongside scalp hair.
Our prescribers, who review every consultation personally, can discuss hair-related concerns as part of your ongoing aftercare. The contact page has the fastest routes to the aftercare team if you are already a patient and want to raise this between scheduled reviews. Seven-day-a-week support is part of the service rather than an add-on.
For a broader look at less-common reactions to semaglutide (including Wegovy and shaking or tremors) the related pages below fill in those gaps. And if you are still deciding whether treatment is right for you, starting a free consultation is the way to get a personalised clinical view rather than a general one. A named prescriber reads your answers; a payday or holiday Monday can mean dispatch the same afternoon once approved, with delivery arriving the next working day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.